JP Patent

JP2025160167A — 転移期前立腺癌を治療する方法

Assigned to Ferring International Center SA · Expires 2025-10-22 · 1y expired

What this patent protects

【課題】対象の転移期前立腺癌を治療するための組成物を提供する。【解決手段】デガレリクスを含む組成物とその使用方法が提供される。【選択図】図１

USPTO Abstract

【課題】対象の転移期前立腺癌を治療するための組成物を提供する。【解決手段】デガレリクスを含む組成物とその使用方法が提供される。【選択図】図１

Drugs covered by this patent

degarelix-acetate (DEGARELIX ACETATE)

Patent Metadata

Patent number: JP2025160167A
Jurisdiction: JP
Classification: —
Expires: 2025-10-22
Drug substance claim: No
Drug product claim: No
Assignee: Ferring International Center SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.